We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
REFERENCES
1
1.Köhler, G., & Milstein, C.Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature, 1975, 256, 495–497.CrossRefGoogle Scholar
2
2.Miller, R. A., Maloney, D. C, Varnke, R., & Levy, R.Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. New England Journal of Medicine, 1982, 306, 517–522.CrossRefGoogle ScholarPubMed
3
3.Koprowski, H., & Herlyn, M. Human tumor antigens. In Wahren, B. (ed.), Progress in cancer research. New York: Raven Press, 1985, 123–139.Google Scholar
4
4.Schroff, R. W., Farrell, M. M., Klein, R. A., Oldham, R. H., & Foon, K. A.T65 antigen modulation in phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. Journal of Immunology, 1984, 133, 1641–1648.CrossRefGoogle ScholarPubMed
5
5.Stevenson, F. K., Glennie, M. J., Johnston, D. M. M., Tutt, A. L., & Stevenson, G. T.Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: A guide for immunotherapy. British Journal of Cancer, 1984, 50, 407–413.CrossRefGoogle ScholarPubMed
6
6.Oldham, R. H., Morgan, A. C., Woodhouse, C. S., Schroff, R. W., Abrams, P. G., & Foon, K. A.Monoclonal antibodies in the treatment of cancer: Preliminary observations and future prospect. Medical Oncology & Tumour Pharmacotherapy, 1984, 1, 51–62.CrossRefGoogle Scholar
7
7.Koprowski, H. Mouse monoclonal antibodies in vivo. In Boss, V. D., Langman, R., Trowbridge, I., & Dulbecco, R. (eds.), Monoclonal antibodies in cancer. New York: Academic Press, 1983, 17–37.Google Scholar
8
8.Hamblin, T. J., Abdul-Ahad, A. K., Gordon, J., Stevenson, F. K., & Stevenson, G. T.Preliminary experience in treating lymphocytic leukemia with antibody to immunoglobulin idiotypes on the cell surfaces. British Journal of Cancer, 1980, 42, 495–502.CrossRefGoogle ScholarPubMed
9
9.Steplewski, Z., Lubeck, M. D., & Koprowski, H.Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science, 1983, 221, 865–867.CrossRefGoogle ScholarPubMed
10
10.Akiyama, Y., Lubec, M. D., Steplewski, Z., & Koprowski, H.Induction of mouse IgG2a – and IgG3-dependent cellular cytotoxicity in human monocytic cells. (U937) by immune interferon. Cancer Research, 1984, 44, 5127–5131.Google ScholarPubMed
11
11.Koprowski, H., Herlyn, D., Lubec, M. D., DeFreitas, E., & Sears, H. F.Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response is beneficial for the patient?Proct Natl Acad Set, 1984, 81, 216–219.CrossRefGoogle ScholarPubMed
12
12.Berd, D., Mastrangelo, M. J., Engström, T. F., Paul, A., & Maguire, H.Augmentation of the human immune response by cyclophosphamide. Cancer Research, 1982, 42, 4862–4862.Google ScholarPubMed
14. A report from the Hammersmith Oncology Group and the Imperial Cancer Research Fund: Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment. The Lancet, 1984, i, 1441–1443.CrossRefGoogle Scholar